Daily Newsletter

29 February 2024

Daily Newsletter

29 February 2024

Empatica launches EpiMonitor epilepsy monitoring system

EpiMonitor has features such as improved seizure alert capabilities, a battery life of up to one week, and advanced health insights.

Archana Rani February 29 2024

Empatica has launched EpiMonitor, an epilepsy monitoring system for adults and children aged six and above.

Approved by the US Food and Drug Administration (FDA), EpiMonitor is an advanced wearable technology designed to detect generalised tonic-clonic seizures with high accuracy.

A successor to Empatica’s Embrace2 device, EpiMonitor has features such as improved seizure alert capabilities, a battery life of up to one week, and advanced health insights.

It operates using Empatica's EmbracePlus medical watch, which has undergone numerous clinical trials.

The companion smartphone app and algorithms work in tandem to monitor health data, detect potential seizures, and alert caregivers promptly.

Empatica said the device has a 98% accuracy rate in seizure detection, with a low false alarm rate, and can send automatic alerts to caregivers via call and SMS, including the user’s location.

EpiMonitor also offers a user-friendly mobile app, which includes a seizure diary, and the ability to track sleep and activity through Empatica’s proprietary algorithms.

Users can also generate reports on seizures, sleep, and activity, which can be shared with physicians.

Furthermore, the system is compatible with both iOS and Android smartphones.

Empatica chief scientist and co-founder Dr Rosalind Picard said: “Empatica has always provided the only smartwatch seizure monitors validated by the FDA.

“Our new solution, Epimonitor, takes this to a new level: giving patients up to 7 days of battery life, and new features that give them greater control over seizure alerts.

“Also, at the touch of a button, patients can now see comprehensive health insights – including seizures, sleep, and activity reports – in a form easy to give their clinician.”

Empatica is planning to undertake a pioneering study to develop a seizure forecasting algorithm, leveraging the largest real-world data set in patients with epilepsy.

Last year, Empatica obtained FDA 510(k) clearance for two new digital biomarkers, namely pulse and respiratory rate, for its health monitoring platform.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close